Furthermore, this analysis highlighted a statistically significant correlation (with p-value = 0.0091) between the combined gene expression of GPX2, EP300, and PSMB2 (Figure 6), and the OS of prostate cancer patients, thus confirming that the combined evaluation of some selenoproteins and HUB nodes, could represent a new strategy to predict patient outcomes. This evidence concerns the gene ELAVL2 and prostate cancer.